Dynamic quotes: Off
|
Company Description (as filed with the SEC)
GenVec, Inc. (GenVec, we, our, or the Company) is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis AG, Merial Limited, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec’s development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, and malaria. In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD). Our core technology has the important advantage of localizing protein delivery in the body. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-1.09 |
| Quarterly EPS Est: | -0.13 |
| PEG Ratio: | .00 |
|
Mean Recommendation: View Summary / View All |
3 |
Data is provided by Zacks Investment Research

